Ibugrip Plus 200 mg / 30 mg x 10 film tablets.

Ibugrip Plus 200 mg / 30 mg x 10 compr. movie.

Ibugrip Plus is recommended to be used to treat symptoms associated with flu or cold, such as: muscle pain, joint pain, headache, fever, accompanied by nasal congestion (sinusitis, rhinosinusitis).

Doses and method of administration:

Adults, adolescents and children over 12 years of age:

The recommended initial dose is 1-2 film-coated tablets. If necessary, the treatment will continue with 1 or 2 film-coated tablets every 4-6 hours. The maximum recommended dose is 6 film-coated tablets in 24 hours (1200 mg ibuprofen).

Children under 12 years of age:

It is not administered to children under 12 years of age and weighing under 40 kg.

Task

The medicine should not be administered during pregnancy, considering that: - inhibition of prostaglandin synthesis by ibuprofen may have a negative influence on pregnancy and/or embryonic/fetal development.

suckling

Administering the drug to breastfeeding women is contraindicated because:

- ibuprofen is excreted in breast milk, although at therapeutic doses during short-term treatment, the risk of affecting the infant seems unlikely;

- pseudoephedrine is excreted in breast milk in large quantities and can cause adverse cardiovascular and neurological reactions in infants.

Contraindications

• Hypersensitivity to the active substances (ibuprofen and pseudoephedrine hydrochloride), acetylsalicylic acid, other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients;
• Patients with a history of hypersensitivity reactions (for example, bronchospasm, bronchial asthma, rhinitis, angioedema or urticaria) associated with the administration of acetylsalicylic acid or other NSAIDs;
• Active gastrointestinal ulcer/hemorrhage or history of recurrent gastrointestinal ulcer/hemorrhage (two or more distinct episodes of proven ulceration or hemorrhage);
• History of gastrointestinal bleeding or perforation related to previous NSAID treatment - patients with severe liver failure, severe renal failure, coronary disease or severe heart failure (NYHA Class IV classification);
• Hematopoietic disorders of unspecified etiology;
• Cerebrovascular hemorrhage or other active hemorrhage;
• Severe or therapeutically uncontrolled hypertension;
• Angina pectoris;
• Diabetes;
• Pheochromocytoma;
• Hyperthyroidism;
• Angle-closure glaucoma;
• Systemic lupus erythematosus;
• Hyperplasia of the prostate;
• Epilepsy;
• Concomitant administration with monoamine oxidase inhibitors (MAOIs) or within two weeks of stopping therapy with an MAOI;

Children under 12 years of age and weighing under 40 kg;

Last trimester of pregnancy.

This is a medicine. It is recommended to carefully read the leaflet or the information on the packaging. If unpleasant manifestations occur, contact your doctor or pharmacist.